Evercore ISI Reaffirms Their Buy Rating on Ibotta, Inc. Class A (IBTA)
In a report released today, Mark Mahaney from Evercore ISI maintained a Buy rating on Ibotta, Inc. Class A (IBTA – Research Report), with ...
Evercore ISI Sticks to Its Buy Rating for Innate Pharma (IPHA)
Evercore ISI analyst Liisa Bayko maintained a Buy rating on Innate Pharma (IPHA – Research Report) today and set a price target of $5.00.